Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) had its target price dropped by research analysts at Robert W. Baird from $85.00 to $80.00 in a research note issued on Friday. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Robert W. Baird’s price target would suggest a potential upside of 61.52% from the stock’s current price.

A number of other equities analysts have also recently commented on RARE. HC Wainwright reaffirmed a “neutral” rating and set a $75.00 price objective (up from $72.00) on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 8th. Jefferies Group LLC reissued a “hold” rating and issued a $68.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, July 14th. Evercore ISI started coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 16th. They issued an “in-line” rating and a $63.00 target price for the company. Stifel Nicolaus reissued a “buy” rating and issued a $85.00 target price (down previously from $95.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. Finally, Canaccord Genuity reissued a “buy” rating and issued a $83.00 target price (down previously from $98.00) on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 22nd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the stock. Ultragenyx Pharmaceutical has a consensus rating of “Hold” and an average target price of $71.31.

Ultragenyx Pharmaceutical (NASDAQ RARE) traded up $1.28 during mid-day trading on Friday, reaching $49.53. 709,442 shares of the company’s stock were exchanged, compared to its average volume of 403,202. Ultragenyx Pharmaceutical has a 1 year low of $44.56 and a 1 year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, hitting the Zacks’ consensus estimate of ($1.87). The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.02 million. During the same period last year, the firm earned ($1.64) earnings per share. The company’s revenue for the quarter was up 81.8% compared to the same quarter last year. equities analysts predict that Ultragenyx Pharmaceutical will post -7.24 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/ultragenyx-pharmaceutical-inc-rare-price-target-cut-to-80-00/1681442.html.

In other news, CEO Emil D. Kakkis purchased 7,500 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, August 28th. The shares were bought at an average cost of $52.52 per share, for a total transaction of $393,900.00. Following the completion of the acquisition, the chief executive officer now owns 430,569 shares in the company, valued at approximately $22,613,483.88. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 9.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Capital Research Global Investors grew its holdings in shares of Ultragenyx Pharmaceutical by 1.4% during the second quarter. Capital Research Global Investors now owns 5,183,330 shares of the biopharmaceutical company’s stock worth $321,937,000 after purchasing an additional 71,811 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 10.4% during the second quarter. BlackRock Inc. now owns 3,497,591 shares of the biopharmaceutical company’s stock worth $217,237,000 after purchasing an additional 330,911 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 4.5% during the second quarter. Vanguard Group Inc. now owns 3,130,273 shares of the biopharmaceutical company’s stock worth $194,421,000 after purchasing an additional 135,335 shares during the last quarter. Capital International Investors boosted its holdings in Ultragenyx Pharmaceutical by 9.1% in the second quarter. Capital International Investors now owns 2,374,985 shares of the biopharmaceutical company’s stock valued at $147,510,000 after acquiring an additional 198,252 shares during the last quarter. Finally, State Street Corp boosted its holdings in Ultragenyx Pharmaceutical by 21.4% in the second quarter. State Street Corp now owns 1,536,285 shares of the biopharmaceutical company’s stock valued at $95,417,000 after acquiring an additional 270,729 shares during the last quarter. Institutional investors own 96.22% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.